CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Funding Request||Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy|
|Review Status||Under Review|
|Pre Noc Submission||Yes|
|NOC Date||October 2, 2020|
|Submission Date||September 21, 2020|
|Submission Deemed Complete||October 5, 2020|
|Stakeholder Input Deadline ‡||October 5, 2020|
|Check-point meeting||November 26, 2020|
|pERC Meeting||February 18, 2021|
|Initial Recommendation Issued||March 4, 2021|
|Feedback Deadline ‡||March 18, 2021|
|pERC Reconsideration Meeting (target date)||April 15, 2021|
|Final Recommendation Issued (target date)||April 29, 2021|
|Notification to Implement Issued|
|Therapeutic Area||First Line OC|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.